imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastična sredstva - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
defitelio
gentium s.r.l. - defibrotid - hepatski veno-okluzivna bolest - antitrombotska sredstva - defitelio je indiciran za liječenje teške jetrene venookluzivna bolest (vod) također poznat kao sinusoidni opstruktivne sindrom (sos) krvotvornih matičnih stanica transplantacija (hsct) terapije. ona je prikazana kod odraslih i kod adolescenata, djecu i dojenčad starija od 1 mjeseca.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
xeljanz 10mg film tableta
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - tofacitinib - film tableta - 10mg
xeljanz 5mg film tableta
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - tofacitinib - film tableta - 5mg
cibinqo 50mg film tableta
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - abrocitinib - film tableta - 50mg
cibinqo 100mg film tableta
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - abrocitinib - film tableta - 100mg
cibinqo 200mg film tableta
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - abrocitinib - film tableta - 200mg
calciumvitac šumeće tablete
krka - farma d.o.o., radnička cesta 48, zagreb - carbonas karbonat, laktat kalcij glukonat, kiselina ascorbicum - šumeća tableta - 260 mg + 500 mg - urbroj: jedna šumeća tableta sadrži 260 mg kalcija u obliku 327 mg kalcijevog karbonata i 1000 mg kalcijevog laktat glukonata, te 500 mg askorbatne kiseline